Global Hepatitis Drugs Market 2017-2023: Second Generation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
613
Global Hepatitis Drugs Market 2017-2023: Second Generation DAAs of Olysio and Sovaldi is a Major Driver

Dublin, March 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Hepatitis Drugs Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering. The Hepatitis Drugs Market to Grow at a CAGR of 15.0% During the Forecast Period 2017-2023 to Aggregate $78.67 Billion By 2023 Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high. The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future. Key Topics Covered: 1 Industry Outlook 1.1 Industry Overview 1.2 Industry Trends 1.3 Pest Analysis 2 Report Outline 2.1 Report Scope 2.2 Report Summary 2.3 Research Methodology 2.4 Report Assumptions 3 Market Snapshot 3.1 Total Addressable Market (TAM) 3.2 Disease Overview 3.2.1 Hepatitis A 3.2.2 Hepatitis B 3.2.3 Hepatitis C 3.2.4 Hepatitis D 3.2.5 Hepatitis E 3.3 Disease Transmission 3.4 Related Markets 4 Market Outlook 4.1 Overview 4.2 Regulatory Bodies & Standards 4.3 Porter 5 (Five) Forces 5 Market Characteristics 5.1 Evolution 5.2 ROADMAP 5.3 Market Dynamics 5.3.1 Drivers 5.3.1.1 Increasing Demand of Hepatitis Drugs 5.3.1.2 Focus on Advanced DAAs 5.3.1.3 Introduction of IFN-free Therapies 5.3.1.4 Growth of Injection Drug Users 5.3.2 Restraints 5.3.2.1 Long Approval Process and Stringent Regulations 5.3.2.2 Side Effects of Hepatitis Drugs 5.3.2.3 Increase in the Number of Generic Drugs 5.3.2.4 Increasing Market Competition 5.3.3 Opportunities 5.3.3.1 Significant Increase in Mergers and Acquisitions 5.3.3.2 Emergence of Combination Drugs 5.3.3.3 Preventive Healthcare 5.3.3.4 Focus of Companies on Emerging Market 5.3.4 DRO - Impact Analysis 6 Trends, Roadmap and Projects 6.1 Market Trends & Impact 6.2 Technology Roadmap 7 Types: Market Size & Analysis 8 Trending Hepatitis Drugs 8.1 Overview 8.1.1 VEMLIDY 8.1.2 EPCLUSA 8.1.3 SOVALDI 8.1.4 INCIVEK 8.1.5 OLYSIO 8.1.6 VICTRELIS 8.1.7 VIREAD 8.1.8 HEPSERA 8.1.9 BARACLUDE 8.1.10 TYZEKA 8.1.11 INTRON A 8.1.12 PEGASYS 8.1.13 PEGINTRON 8.1.14 ROFERON-A 8.1.15 VIRAFERONPEG 8.1.16 REBETOL 9 Regions: Market Size & Analysis 9.1 OVERVIEW 9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation 10 Vendor Scenario 10.1 Market Share Ranking 2016 10.1.1 GILEAD SCIENCES INC. 10.1.1.1 Sovaldi (sofosbuvir) 10.1.1.2 Harvoni (ledipasvir and sofosbuvir) 10.1.1.3 Viread (tenofovir disoproxil fumarate) 10.1.1.4 Hepsera (adefovir dipivoxil) 10.1.2 ABBVIE INC. 10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) 10.1.3 JOHNSON & JOHNSON 10.1.3.1 Olysio (simeprevir) 10.1.3.2 Incivo(telaprevir) 10.1.4 MERCK & CO. INC. 10.1.4.1 Zepatier (elbasvir and grazoprevir) 10.1.4.2 Victrelis (boceprevir) 10.1.4.3 Peg-Intron (peginterferon alfa-2b) 10.1.4.4 Rebetol (ribavirin) 10.1.4.5 Intron A (interferon alfa-2b, recombinant) 10.1.5 GLAXOSMITHKLINE PLC 10.1.5.1 Pediarix Vaccine 10.1.5.2 Twinrix 10.1.5.3 Havrix 10.1.5.4 Epivir (lamivudine) 10.1.6 VERTEX PHARMACEUTICALS INC. 10.1.6.1 Incivek (telaprevir) 10.1.7 NOVARTIS AG 10.1.7.1 Tyzeka (telbivudine) 10.1.8 HOFFMANN-LA ROCHE LTD. 10.1.8.1 Pegasys (peginterferon alfa-2a) 11 Vendor Profiles 11.1.1 Merck & Co. Inc. 11.1.2 Hoffmann-La Roche Ltd. 11.1.3 Gilead Sciences 11.1.4 Novartis AG 11.1.5 GlaxoSmithKline plc 12 Global Generalist 12.1 Vertex Pharmaceuticals Inc. 12.2 Johnson & Johnson 13 Market Landscape 13.1 Market Landscape 13.1.1 Mergers & Acquisitions (M&A) For more information about this report visit http://www.researchandmarkets.com/research/9s..._hepatitis

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Liver and Kidney Disorders Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Opens New Café in Novato, CA

Updated Category News Views 76

Another Feather in Paris Baguette’s Cap Alright, as far as pastry shops go, Paris Baguette is rolling out those cinnamon rolls like they're planting flags on the moon. They've just added a new café in Novato, California, bringing the artisanal charm of their iconic baked goods to yet another American doorstep. A Local Affair with Big Aspirations The man of the hour,...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 214

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 131

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
IEHP's Wellness Center Launch Faces Delay in California

Updated Category News Views 80

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Continue Reading
Navigating Roof Damage Insurance Claims: Key Insights

Updated Category News Views 135

No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...

Continue Reading
KeyCorp Plans Redemption of Series E Preferred Stock

Updated Category News Views 112

KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...

Continue Reading
Honoring Boston's Architects Changing the Game

Updated Category News Views 75

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

Continue Reading
SOCSA: The Future of Safety in Confined Spaces?

Updated Category News Views 100

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 62

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading

Top 5 Most Recently Viewed Articles

Dr. Mark Adams Takes the Helm as NDX's New President

Updated Category News Views 698

Dr. Mark Adams Takes the Helm as NDX's New President National Dentex Labs (NDX), a well-regarded provider of dental prosthetics and laboratory solutions, recently announced the appointment of Dr. Mark Adams as their new President. This strategic move positions the company for significant growth and innovation in the dental industry. Dr. Adams: A Proven Leader in Dentistry...

Continue Reading
Firefly Metals Secures C$30 Million Financing for Growth

Updated Category News Views 243

Firefly Metals Ltd Partners with BMO for Financing Firefly Metals Ltd (ASX: FFM, TSX: FFM), a rising star in the copper and gold sector, recently disclosed an agreement with BMO Nesbitt Burns Inc. This partnership is poised to solidify the company’s financial standing by instituting a bought deal financing arrangement, which is expected to yield C$30 million...

Continue Reading
Bird Construction Reports Impressive Q3 Growth and Impactful Acquisitions

Updated Category News Views 153

Bird Construction Achieves Remarkable Q3 Financial Results Bird Construction Inc. has recently shared robust financial outcomes for the third quarter, underscoring its growth and profitability trajectory. During this period, Bird Construction built on its earlier successes from the first half of the year, demonstrating solid momentum as it seeks a commendable finish to...

Continue Reading
KeyBank Partners with Zentist to Enhance Dental Revenue Cycles

Updated Category News Views 88

Understanding the Partnership Between KeyBank and Zentist Recently, KeyCorp (NYSE: KEY) formed a strategic partnership with Zentist, a well-regarded software provider that focuses on Insurance Revenue Cycle Management (RCM) for Dental Support Organizations (DSOs). This collaboration includes a minority investment designed to improve the financial operations of dental...

Continue Reading
Market Trends Shifting as Procter & Gamble Takes Center Stage

Updated Category News Views 306

Procter & Gamble: Analyzing Market Whales' Moves Recent trading activity surrounding Procter & Gamble (NASDAQ: PG) has captured the attention of financial analysts and investors alike. A remarkable bullish trend has emerged, as major traders initiate 16 unusual options trades reflecting confidence in this enduring brand. Understanding the Trader Sentiment Our assessment...

Continue Reading